June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Modulating p75NTR protects against ischemic retinopathy via increased vascular homing of mesenchymal stem cells
Author Affiliations & Notes
  • Sally L Elshaer
    Clinical and Administrative Pharmacy, University of Georgia, Augusta, Georgia, United States
    Charlie Norwood VA Medical Center, Augusta, Georgia, United States
  • William Dave Hill
    Augusta University, Augusta, Georgia, United States
    Charlie Norwood VA Medical Center, Augusta, Georgia, United States
  • Rajashekhar Gangaraju
    Hamilton Eye Institute, Memphis, Tennessee, United States
  • Azza B El-Remessy
    Clinical and Administrative Pharmacy, University of Georgia, Augusta, Georgia, United States
    Charlie Norwood VA Medical Center, Augusta, Georgia, United States
  • Footnotes
    Commercial Relationships   Sally Elshaer, None; William Dave Hill, None; Rajashekhar Gangaraju, None; Azza El-Remessy, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4584. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sally L Elshaer, William Dave Hill, Rajashekhar Gangaraju, Azza B El-Remessy; Modulating p75NTR protects against ischemic retinopathy via increased vascular homing of mesenchymal stem cells. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4584.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ischemic retinopathy is characterized by initial ischemia that progresses into neovascularization. We reported that deletion of death receptor; p75NTR enhanced vascular repair in oxygen-induced retinopathy model and preserved expression of angiogenic markers; SDF-1, CXCR-4 and CXCR-7 responsible for mesenchymal stem cells (MSCs) homing to vasculature in diabetic ischemic limbs. MSCs are potential candidates for neuro-regeneration in various retinal diseases, nevertheless, their role in retinal vascular repair remains poorly addressed. Our aim is to investigate the contribution of MSCs to vascular protection associated with p75NTR deletion in ischemic retina.

Methods : WT and p75NTR-/- mice were subjected to retinal ischemia reperfusion (I/R) injury. Murine GFP-labeled p75NTR-positive or p75NTR-null MSCs were injected intravitreally 2 days post-I/R and vascular homing was assessed one week later. Acellular capillaries were counted on trypsin-digested retinas 10 days post I/R. In vitro, MSCs were treated with a specific pharmacological inhibitor against p75NTR; LM11A-31 and conditioned media was co-cultured with human retinal endothelial cells (HRECs) to examine angiogenic response.

Results : p75NTR-/- ischemic retinas showed 2-Fold increase in acellular capillaries compared to 3-Fold increase in WT as well as preserved mRNA expression of CXCR-7. p75NTR-MSCs showed best incorporation into ischemic retinal vasculature one-week post-injection and completely protected against acellular capillaries in ischemic p75NTR-/- retinas. p75NTR-null MSCs showed better incorporation into WT ischemic retinal vasculature and significantly decreased acellular capillaries by 60% compared to ischemic WT receiving p75NTR-MSCs. p75NTR-null MSCs showed increased mRNA expression of CXCR-4 as well as increased mRNA and protein expression of CXCR-7. In vitro, inhibition p75NTR in MSCs enhanced angiogenic response of their conditional media in HRECs, where HRECs showed enhanced migration (1.3-Fold) and tube formation (2.7-Fold).

Conclusions : Our results showed that deletion of p75NTR protects against retinal ischemia by mechanisms involving improved MSCs homing to ischemic vasculature to prevent vascular degeneration. Thus, combination of MSCs injection and p75NTR inhibitor can serve as potential therapeutic strategy to harness vascular repair in ischemic retinopathy diseases.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×